ArticleBMC cancer2026
Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe circadian clock regulates tumor-immune interactions in a time-of-day-dependent manner, yet whether this translates to a clinically meaningful benefit across diverse solid tumors in real-world populations remains unclear.
methodsWe retrospectively analyzed 969 patients receiving anti-PD-1 or anti-PD-L1 therapy at UCI Health between 2018 and 2022. Patients were classified as early (before 12 PM) or late (12 PM or after) based on infusion time. The primary outcome was disease control rate (DCR), defined as complete response (CR), partial response (PR), or stable disease (SD) per RECIST criteria. Unadjusted comparisons used the Pearson chi-square test. Multivariable logistic regression adjusting for disease stage, age, and ethnicity was performed in 806 patients with complete covariate data. Propensity score-matched analyses and sensitivity analyses using alternative exposure definitions were conducted.
resultsEarly infusion was associated with significantly higher DCR compared with late infusion (49% vs. 40%, p = 0.007). This association persisted after multivariable adjustment (adjusted OR 1.18, 95% CI 1.02-1.38, p = 0.024). The effect was directionally consistent across subgroups defined by sex, age, stage, and ICI agent. In ethnicity-stratified analyses, the association was significant among non-Hispanic patients (adjusted OR 1.18, 95% CI 1.02-1.39) but was indeterminate among Hispanic patients due to limited sample size (adjusted OR 1.18, 95% CI 0.84-1.65); the ethnicity-by-TOD interaction term was non-significant (p = 0.958). Sensitivity analyses using alternative exposure definitions and propensity score matching yielded consistent results.
conclusionsIn a large, heterogeneous real-world cohort spanning multiple tumor types and a diverse patient population, early ICI administration was independently associated with higher DCR. These findings support a chronotherapeutic effect of ICI timing and underscore DCR as a sensitive endpoint for its detection. Prospective validation across tumor types and demographic subgroups is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.